Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.
Actively Recruiting
Researchers are studying the effects of fenfluramine hydrochloride compared to a placebo in people with Rett syndrome, a genetic neurological disorder. This Phase 3 clinical trial aims to assess how well fenfluramine hydrochloride works and its safety in improving symptoms of Rett syndrome, with outcomes measured by changes in behavior and clinical impressions over 14 weeks. Participants receive fenfluramine hydrochloride or placebo orally during a 14-week double-blind period, including dose adjustment and maintenance. After this, all participants enter a 2-week transition period, then a 52-week open-label phase where they receive fenfluramine hydrochloride. Those who stop treatment without continued access undergo an 8-day medication taper and a 26-week follow-up. Throughout the trial, participants undergo assessments including questionnaires on behavior, sleep, communication, and caregiver impressions, as well as heart monitoring via ECG and echocardiograms to watch for side effects. Safety and adverse events are tracked up to nearly four years. The study involves regular visits during treatment and follow-up periods, aiming to measure changes in Rett syndrome symptoms and overall clinical status.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.
Actively Recruiting
Researchers are evaluating the clinical and endoscopic effects of guselkumab in children aged 2 to 17 with moderately to severely active Crohns Disease who responded to the treatment by Week 12. The study aims to assess the benefits of guselkumab after one year of maintenance therapy. This is a Phase 3 trial sponsored by Janssen Research & Development, LLC. Participants initially receive guselkumab either intravenously or subcutaneously according to their body weight during a 12-week open-label induction phase. Those who respond by Week 12 are then randomly assigned to one of two guselkumab subcutaneous dosing regimens for a double-blind maintenance phase lasting up to Week 48. Participants who do not respond by Week 12 enter an open-label maintenance phase receiving guselkumab subcutaneously up to Week 48. Throughout the study, participants undergo clinical evaluations, endoscopic assessments, and measurement of guselkumab levels at regular intervals up to Week 52. Researchers monitor changes in clinical remission, endoscopic response, growth parameters such as height and weight, and record any adverse events up to Week 64. The total participation duration extends to approximately one year, with ongoing safety and efficacy assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Researchers are evaluating the use of mirikizumab in children and adolescents aged 2 to 17 years with moderately to severely active Crohns disease. The study aims to assess the drugs effectiveness, safety, tolerability, and how well it is absorbed in the body. This phase 3 clinical trial involves participants with confirmed Crohns disease or fistulizing Crohns disease who have shown an inadequate response or intolerance to at least one prior medication. Participants will receive mirikizumab intravenously or subcutaneously, with dosing based on their weight category. The study includes a 12-week induction period, followed by a maintenance phase lasting from week 12 to week 52. After the treatment periods, there is a safety follow-up period lasting up to 16 weeks. Overall, the study will last approximately 74 weeks and may involve up to 19 visits. Throughout the study, participants will undergo various assessments including clinical response evaluations using the Pediatric Crohns Disease Activity Index PCDAI and endoscopic scoring. Researchers will monitor changes in inflammatory markers such as C-reactive protein and fecal calprotectin, as well as pharmacokinetic measures of mirikizumab. Safety and tolerability will be tracked during the follow-up period, with all evaluations scheduled at multiple timepoints throughout the study.
1-10 of 30
1